CSO: Dr. Eyal Ben Ami
MOYA Bio is developing novel E1 inhibitors for solid and hematological malignancies. The proprietary compounds developed by the company modulate the Ubiquitin and Ubiquitin-Like (UBL) pathways in a targeted and highly selective manner and are envisioned to not only induce direct anti-tumoral effects but also increase the impact of additional treatment modalities.
The clinical success of proteasome inhibitors (e.g., bortezomib or carfilzomib) has piqued interest in targeting other components of the Ubiquitin-Proteasome System as well as closely related Ubiquitin-Like (UBL) pathways. Among these, antagonism of E1 enzymes, which instigate the different UBL cascades, has been highlighted as a promising therapeutic approach in cancer. MOYA Bio has developed a series of novel proprietary E1 antagonists that target specific UBL pathways and hold significant anti-cancer activity, which are currently under preclinical development.